Ogden Christopher 4
4 · CytomX Therapeutics, Inc. · Filed Jun 17, 2025
Insider Transaction Report
Form 4
Ogden Christopher
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-06-13+37,500→ 236,885 total - Exercise/Conversion
Performance Stock Units
2025-06-13−37,500→ 0 total→ Common Stock (37,500 underlying) - Sale
Common Stock
2025-06-13$2.95/sh−1,641$4,841→ 199,385 total - Sale
Common Stock
2025-06-16$2.69/sh−10,614$28,540→ 226,271 total
Footnotes (5)
- [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- [F2]Includes 149,987 RSUs.
- [F3]This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023.
- [F4]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
- [F5]Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.